Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 368,490 |
|
|||||
| News | - | ||||||
| Day High | 1.2599 | Low High |
|||||
| Day Low | 1.19 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Allakos Inc | ALLK | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.03 | 2.48% | 1.24 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.22 | 1.19 | 1.2599 | 1.25 | 1.21 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,348 | 368,490 | US$ 1.22 | US$ 448,756 | - | 0.9799 - 5.64 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 17:03:09 | 15 | US$ 1.2306 | USD |
Allakos Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 109.84M | 87.87M | - | 0 | -185.7M | -2.11 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Allakos News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALLK Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.33 | 1.47 | 1.18 | 1.33 | 606,669 | -0.09 | -6.77% |
| 1 Month | 1.15 | 1.51 | 1.11 | 1.32 | 507,717 | 0.09 | 7.83% |
| 3 Months | 1.36 | 1.51 | 0.9799 | 1.25 | 492,167 | -0.12 | -8.82% |
| 6 Months | 2.18 | 3.405 | 0.9799 | 1.64 | 1,120,988 | -0.94 | -43.12% |
| 1 Year | 4.75 | 5.64 | 0.9799 | 2.41 | 1,048,613 | -3.51 | -73.89% |
| 3 Years | 101.76 | 112.87 | 0.9799 | 9.02 | 1,320,578 | -100.52 | -98.78% |
| 5 Years | 39.17 | 157.98 | 0.9799 | 20.48 | 926,908 | -37.93 | -96.83% |
Allakos Description
| Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells. |
